Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host, pharmacist, Derek Christensen,

and I thank you so much for listening today. As always, go check out real-life pharmacology.com. Get your

free 31-page PDF on the top 200 drugs. It's a great study guide, no-brainer for those in clinical

practice or those going through pharmacology courses.

So simply an email, we'll get you access to that.

We also get you updates when we've got other new content available as well.

All right, let's get into the drug of the day today, and that is moxacam.

Brand name of this medication is Mobek.

And this is an insed.

Just a quick reminder, insed stands for non-steroidal, anti-inflammatory drug.

Some of the common ensets, ibuprofen, naproxin, those are over-the-counter,

and probably the two most common that I see in practice.

But I do occasionally see molyxicam.

So with that mechanism of being an N-Sed, this medication inhibits Cox enzymes,

and specifically Cox 1 and Cox 2.

That ultimately reduces prostaglandin synthesis,

which can lead to a reduction in pain and inflammation.

Now let's talk specifically about Meloxicam.

Meloxicam tends to prefer Cox 2 over Cox 1.

Now, as you increase doses, that selectivity tends to go away,

and you get Cox 1 and Cox 2 inhibition.

But what that means is if we've got a little bit of a preference towards cox two inhibition

...